"Analysis.group","Analysis.number","Analysis.name","Subgroup","Applicability","Study","Study.year","GIV.Mean","GIV.SE","Experimental.mean","Experimental.SD","Experimental.cases","Experimental.N","Control.mean","Control.SD","Control.cases","Control.N","O.E","Variance","Weight","Mean","CI.start","CI.end","Footnotes","review.url","review.doi","analysis_key","dataset_name","mismatch_type","direction_match","or_sig","rd_sig","log_or","rd","log_or_ci_lb","log_or_ci_ub","rd_ci_lb","rd_ci_ub","sparse_events","double_zero"
1,1,"Rivaroxaban versus antiplatelet therapy",NA,"SUBGROUP_AND_OVERALL","GALILEO 2020",2020,0,0,0,0,64,826,0,0,38,818,0,0,100,1.667899,1.129745,2.462402,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013745.pub2/full","10.1002/14651858.CD013745.pub2","1::overall","CD013745_pub2_data","significance_only",TRUE,TRUE,FALSE,0.279073733595363,0.00363468738750899,0.0281581225312312,0.529989344659495,-0.00330163239184991,0.0105710071668679,FALSE,FALSE
2,1,"Rivaroxaban versus antiplatelet therapy",NA,"SUBGROUP_AND_OVERALL","GALILEO 2020",2020,0,0,0,0,35,826,0,0,27,818,0,0,100,1.283741,0.784387,2.100992,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013745.pub2/full","10.1002/14651858.CD013745.pub2","1::overall","CD013745_pub2_data","significance_only",TRUE,TRUE,FALSE,0.279073733595363,0.00363468738750899,0.0281581225312312,0.529989344659495,-0.00330163239184991,0.0105710071668679,FALSE,FALSE
3,1,"Rivaroxaban versus antiplatelet therapy",NA,"SUBGROUP_AND_OVERALL","GALILEO 2020",2020,0,0,0,0,30,826,0,0,25,818,0,0,100,1.188378,0.705187,2.002648,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013745.pub2/full","10.1002/14651858.CD013745.pub2","1::overall","CD013745_pub2_data","significance_only",TRUE,TRUE,FALSE,0.279073733595363,0.00363468738750899,0.0281581225312312,0.529989344659495,-0.00330163239184991,0.0105710071668679,FALSE,FALSE
4,1,"Rivaroxaban versus antiplatelet therapy",NA,"SUBGROUP_AND_OVERALL","GALILEO 2020",2020,0,0,0,0,30,826,0,0,15,818,0,0,100,1.98063,1.073803,3.653272,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013745.pub2/full","10.1002/14651858.CD013745.pub2","1::overall","CD013745_pub2_data","significance_only",TRUE,TRUE,FALSE,0.279073733595363,0.00363468738750899,0.0281581225312312,0.529989344659495,-0.00330163239184991,0.0105710071668679,FALSE,FALSE
5,1,"Rivaroxaban versus antiplatelet therapy",NA,"SUBGROUP_AND_OVERALL","GALILEO 2020",2020,0,0,0,0,23,826,0,0,17,818,0,0,100,1.339838,0.7212,2.489137,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013745.pub2/full","10.1002/14651858.CD013745.pub2","1::overall","CD013745_pub2_data","significance_only",TRUE,TRUE,FALSE,0.279073733595363,0.00363468738750899,0.0281581225312312,0.529989344659495,-0.00330163239184991,0.0105710071668679,FALSE,FALSE
6,1,"Rivaroxaban versus antiplatelet therapy",NA,"SUBGROUP_AND_OVERALL","GALILEO 2020",2020,0,0,0,0,3,826,0,0,2,818,0,0,100,1.485472,0.248864,8.86679,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013745.pub2/full","10.1002/14651858.CD013745.pub2","1::overall","CD013745_pub2_data","significance_only",TRUE,TRUE,FALSE,0.279073733595363,0.00363468738750899,0.0281581225312312,0.529989344659495,-0.00330163239184991,0.0105710071668679,FALSE,FALSE
7,1,"Rivaroxaban versus antiplatelet therapy",NA,"SUBGROUP_AND_OVERALL","GALILEO 2020",2020,0,0,0,0,1,826,0,0,4,818,0,0,100,0.247579,0.027731,2.210339,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013745.pub2/full","10.1002/14651858.CD013745.pub2","1::overall","CD013745_pub2_data","significance_only",TRUE,TRUE,FALSE,0.279073733595363,0.00363468738750899,0.0281581225312312,0.529989344659495,-0.00330163239184991,0.0105710071668679,FALSE,FALSE
8,1,"Rivaroxaban versus antiplatelet therapy",NA,"SUBGROUP_AND_OVERALL","GALILEO 2020",2020,0,0,0,0,3,826,0,0,7,818,0,0,100,0.424421,0.110132,1.635606,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013745.pub2/full","10.1002/14651858.CD013745.pub2","1::overall","CD013745_pub2_data","significance_only",TRUE,TRUE,FALSE,0.279073733595363,0.00363468738750899,0.0281581225312312,0.529989344659495,-0.00330163239184991,0.0105710071668679,FALSE,FALSE
9,1,"Rivaroxaban versus antiplatelet therapy",NA,"SUBGROUP_AND_OVERALL","GALILEO 2020",2020,0,0,0,0,2,97,0,0,11,101,0,0,100,0.189316,0.043068,0.832193,NA,"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013745.pub2/full","10.1002/14651858.CD013745.pub2","1::overall","CD013745_pub2_data","significance_only",TRUE,TRUE,FALSE,0.279073733595363,0.00363468738750899,0.0281581225312312,0.529989344659495,-0.00330163239184991,0.0105710071668679,FALSE,FALSE
